Immunotherapy Safe and Effective for Cancer Patients With HIV Infection

Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, and CTLA-4 have become key treatments for many advanced cancers due to their ability to induce durable responses and prolong survival. Patients with human immunodeficiency virus (HIV) infection are at increased risk of developing cancer, such as lung cancer, head and neck cancer, anal cancer, and Hodgkin lymphoma, […]

Read More

Stereotactic Radiation Improves Survival in Inoperable Stage I NSCLC

Patients with stage I non-small cell lung cancer (NSCLC), who are not eligible for surgical resection, can still potentially be cured with radiotherapy alone. Advances in radiotherapy technology have led to the development of stereotactic ablative body radiotherapy (SABR), a technique that enables very precise delivery of high-radiation (ablative) doses to small tumors in a […]

Read More

Immune Checkpoint Inhibitors Effective in KRAS-Mutant NSCLC

More than 30% of patients with advanced non-small cell lung cancer (NSCLC) carry mutations in the KRAS gene. Mutated KRAS is associated with a poor prognosis, and there are currently no effective targeted therapies directed against this mutation. Immunotherapy with immune checkpoint inhibitors (ICI) targeting PD-1 and PD-L1 have become a standard treatment option for […]

Read More

Dose-Intense Chemotherapy Considerations in Early Breast Cancer

Adjuvant chemotherapy with an anthracycline and a taxane became a standard of care in early breast cancer based on reduced risk of breast cancer mortality by a third, when compared to no chemotherapy. Several trials have since examined strategies to further improve outcomes with more dose-intense chemotherapy regimens, either by giving chemotherapy more frequently or […]

Read More

Five Interesting Articles Worth Reading

Clinical Cancer Advances in 2019. The American Society of Clinical Oncology (ASCO) released its annual report on progress in cancer treatment. This important article highlights some of the major breakthroughs in solid and hematologic malignancies in the past year, with special attention to advances in treating rare cancers. The authors also identify several areas for […]

Read More

No Benefit for Adding Docetaxel to ADT in Localized Prostate Cancer

Within 10 years of primary treatment (radical prostatectomy and/or radiotherapy) for localized prostate cancer, up to 30% of patients develop biochemical relapse with raising prostate-specific antigen (PSA). On average, biochemical relapse precedes the appearance of clinical metastases by about 8 to 10 years. Factors that indicate high risk for early development of metastases include a […]

Read More